The United States is a leading market for granulocyte-colony stimulating factor (G-CSF) therapies, driven by the increasing incidence of cancer, widespread use of chemotherapy, and strong adoption of biologic and biosimilar treatments. Advanced healthcare infrastructure, growing investments in oncology care, and ongoing biotechnology innovations have enhanced the availability and utilization of...